JonesResearch downgraded Equillium (EQ) to Hold from Buy without a price target after the company announced that Ono Pharmaceutical (OPHLY) declined the option to acquire itolizumab. Equillium now has full commercial rights, “but there are several roadblocks,” the analyst tells investors in a research note. The firm prefers to wait on the sidelines until Equillium resolves the regulatory and trial design issues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EQ: